Phospholipase A2-mediated surfactant hydrolysis and dysfunction in ALI and ARDS
Phospholipase A2-mediated surfactant hydrolysis and dysfunction in ALI and ARDS
批准号:
7261646
负责人:
Robert Duncan Hite
金额:
$36.64万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-05-01 至 2012-03-31
关键词:
AcuteAcute Lung InjuryAcute respiratory failureAddressAdult Respiratory Distress SyndromeAirAlveolarBindingBiochemicalBronchoalveolar LavageBronchoalveolar Lavage FluidCell modelCellsClinicalClinical DataEducational workshopEpithelial CellsEtiologyFamilyFilmFunctional disorderGene ActivationGenesHydrolysisIn VitroIndividualInflammatoryInjuryIntervention StudiesLeukocytesLipidsLiquid substanceLungLysophospholipidsMeasuresMediatingMediator of activation proteinMessenger RNAModelingMultiple AbnormalitiesNewborn Respiratory Distress SyndromeOutcomePathogenesisPathway interactionsPatientsPatternPhasePhosphatidyl glycerolPhosphatidylglycerolsPhospholipase A2PhospholipidsPlayProductionPropertyProteinsPulmonary Surfactant-Associated Protein BPulmonary SurfactantsRecombinantsRecoveryRegulationResearch PersonnelRespiratory FailureRespiratory physiologyRoleSamplingSubstrate SpecificitySurfaceTestingTimeVariantcytokinein vivomacrophagemultidisciplinaryneutrophilpressureprogramssurfactantsurfactant deficiency
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Surfactant deficiency and injury is an important component in the pathogenesis of acute lung injury (ALI)and acute respiratory distress syndrome (ARDS). Analysis of bronchoalveolar lavage (BAL) samples from ALI/ARDS patients reveal multiple abnormalities including decreased total surfactant phospholipid with a disproportionately greater decrease in phosphatidylglycerol (PG). PG is critical to maintain optimal surface activity through its interactions with surfactant protein B (SP-B). Secretory phospholipases A2 (sPLA2) are potent mediators of surfactant injury, and are increased in the BAL fluid in ALI/ARDS. Depletion of PG is a key mechanism in sPLA2-mediated surfactant dysfunction. Identification of specific sPLA2 and mechanisms regulating secretion are unknown in ARDS. This proposal will examine the hypothesis that specific secretory phospholipases A2 released during the inflammatory phase of ALI and ARDS hydrolyze pulmonary surfactant phospholipids, decrease PG and play a major role in limiting endogenous surfactant function and clinical recovery from acute respiratory failure. This hypothesis will be tested as follows:
Specific Aim 1. Measure bronchoalveolar phospholipase A2 and surfactant abnormalities during the
course of ALI/ARDS. BAL fluid will be obtained from ALI/ARDS patients (n = 80) early in the course of
respiratory failure and serial samples will be obtained over the course of respiratory failure. Components of the BAL (cells, surfactant pellet and supernatant) will be analyzed and the associations with important clinical variables of ARDS etiology, respiratory failure and ARDS outcome will be established. Specific Aim 2. Determine the mechanisms regulating sPLA2 expression and secretion. sPLA2 proteins secreted into the BAL will be identified and the regulation of sPLA2 synthesis and release from cell models measured in vitro to test the hypothesis that there is a cytokine driven stimulation of sPLA2 secretion from specific cells in the lung. Cytokine analysis of the BALs in Aim 1 will be used to further direct these studies. Specific Aim 3. Determine the mechanisms that regulate sPLA2-mediated surfactant hydrolysis and dysfunction. The impact of the surfactant proteins (SP) and the alveolar phospholipid forms (bulk aggregates in the subphase and monomolecular films at the air-liquid interface) on sPLA2 hydrolysis, PG depletion and surfactant dysfunction will be examined. Interpretation of the in vivo relevance of these results will be enhanced by measuring SP levels in the BALs from Aim 1. This multicenter, multidisciplinary analysis directly addresses the NHLBI ALI Workshop priority to investigate biochemical predictors of ALI, and is essential to develop effective clinical intervention studies involving suppression of sPLA2 activity and surfactant replacement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ohio Consortium Clinical Center for the NHLBI Prevention and Early Treatment of A
-
批准号:8707155
-
项目类别:
-
资助金额:$16.07万
-
财政年份:2014
-
负责人:Robert Duncan Hite
-
依托单位:
Ohio Consortium Clinical Center for the NHLBI Prevention and Early Treatment of A
-
批准号:9064199
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2014
-
负责人:Robert Duncan Hite
-
依托单位:
Phospholipase A2-mediated surfactant hydrolysis and dysfunction in ALI and ARDS
-
批准号:7781293
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2007
-
负责人:Robert Duncan Hite
-
依托单位:
Phospholipase A2-mediated surfactant hydrolysis and dysfunction in ALI and ARDS
-
批准号:7414068
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2007
-
负责人:Robert Duncan Hite
-
依托单位:
Phospholipase A2-mediated surfactant hydrolysis and dysfunction in ALI and ARDS
-
批准号:7586232
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2007
-
负责人:Robert Duncan Hite
-
依托单位:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
-
批准号:8328484
-
项目类别:
-
资助金额:$26.58万
-
财政年份:2005
-
负责人:Robert Duncan Hite
-
依托单位:
PAC VS CVC FOR MANAGEMENT OF ACUTE LUNG INJURY AND ARDS
-
批准号:7203818
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2005
-
负责人:Robert Duncan Hite
-
依托单位:
ARDS - EDEN Protocol
-
批准号:7824240
-
项目类别:
-
资助金额:$22.79万
-
财政年份:2005
-
负责人:Robert Duncan Hite
-
依托单位:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
-
批准号:8429029
-
项目类别:
-
资助金额:$8.01万
-
财政年份:2005
-
负责人:Robert Duncan Hite
-
依托单位:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
-
批准号:8020416
-
项目类别:
-
资助金额:$77.49万
-
财政年份:2005
-
负责人:Robert Duncan Hite
-
依托单位:
ARDS - SAILS Protocol
-
批准号:8429032
-
项目类别:
-
资助金额:$19.46万
-
财政年份:2005
-
负责人:Robert Duncan Hite
-
依托单位:
PAC vs CVC for Management of Acute Lung Injury and ARDS
-
批准号:7045687
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2004
-
负责人:Robert Duncan Hite
-
依托单位:
CLINICAL CENTER FOR ARDS
-
批准号:6370268
-
项目类别:
-
资助金额:$25.11万
-
财政年份:2000
-
负责人:Robert Duncan Hite
-
依托单位:
海外基金